scholarly journals Renal Disease in Multiple Myeloma

10.5772/33149 ◽  
2012 ◽  
Author(s):  
Guray Saydam ◽  
Fahri Sahin ◽  
Hatice Demet
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease

Fatal case of Herbaspirillum seropedicae bacteremia secondary to pneumonia in an end-stage renal disease patient with multiple myeloma

2015 ◽  
Vol 82 (4) ◽  
pp. 331-333 ◽  
Author(s):  
Nuntra Suwantarat ◽  
La’Tonzia L. Adams ◽  
Mark Romagnoli ◽  
Karen C. Carroll
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Fatal Case ◽  
Disease Patient ◽  
Herbaspirillum Seropedicae ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

2020 ◽  
Author(s):  
Joaquín Martínez-López ◽  
María-Victoria Mateos ◽  
Cristina Encinas ◽  
Anna Sureda ◽  
José Ángel Hernández-Rivas ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factors ◽  
Renal Disease ◽  
Cancer Patients ◽  
Case Series ◽  
Clinical Severity ◽  
Collaborative Group ◽  
List Type ◽  
Inpatient Mortality ◽  
Increased Risk

ABSTRACTThere is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age was 71 years and 57% of patients were male in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.Key PointsThere is an increased risk of inpatient mortality (34% vs 23%) in MM vs age-/sex-matched non-cancer patients hospitalized with COVID-19.Adverse prognostic factors at admission for inpatient mortality in MM patients include age >65 y, male sex, renal disease, and active MM.

scholarly journals Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Blood ◽  
2020 ◽  
Vol 136 (26) ◽  
pp. 3033-3040 ◽  
Author(s):  
Ajai Chari ◽  
Mehmet Kemal Samur ◽  
Joaquin Martinez-Lopez ◽  
Gordon Cook ◽  
Noa Biran ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Renal Disease ◽  
Univariate Analysis ◽  
Staging System ◽  
Outcome Data ◽  
Careful Consideration ◽  
Hospitalized Patients ◽  
Related Factors ◽  
Data Set

Abstract The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19–infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

scholarly journals Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Holly Lee ◽  
Peter Duggan ◽  
Ernesta Paola Neri ◽  
Jason Tay ◽  
Victor Jimenez Zepeda
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Clinical Practice ◽  
B Cells ◽  
Renal Disease ◽  
Maintenance Therapy ◽  
Membranoproliferative Glomerulonephritis ◽  
Monoclonal Gammopathy ◽  
Renal Survival ◽  
Monoclonal Proteins

Monoclonal gammopathy of renal significance (MGRS) defines renal disease resulting from monoclonal proteins that are secreted from clonal B cells, that does not meet criteria for lymphoma or multiple myeloma. Recognizing MGRS in clinical practice is important because renal outcomes are poor and treatments targeting the underlying clonal disease have been associated with improved renal survival. In this case report, we present a case of a patient with membranoproliferative glomerulonephritis (MPGN) with IgG-kappa deposition who underwent clone directed treatment in a phased approach with induction and maintenance to achieve renal response. This is one of the first cases to report on MGRS treatment that required extended maintenance therapy.

Tolerability of Dose Escalation of Ibandronate in Patients with Multiple Myeloma and End-Stage Renal Disease: A Case Series

Onkologie ◽  
2009 ◽  
Vol 32 (8-9) ◽  
pp. 482-486 ◽  
Author(s):  
Dirk M. Henrich ◽  
Martin Hoffmann ◽  
Michael Uppenkamp ◽  
Raoul Bergner
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease ◽  
Dose Escalation ◽  
End Stage Renal Disease ◽  
Case Series ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease

2019 ◽  
Vol 103 (11) ◽  
pp. 2366-2372 ◽  
Author(s):  
Thomas R. Spitzer ◽  
Nina Tolkoff-Rubin ◽  
A. Benedict Cosimi ◽  
Steven McAfee ◽  
Bimalangshu R. Dey ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Leukocyte Antigen ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Monoclonal Gammopathy of Renal Significance—A Rare Renal Presentation: A Review of Cases Reported

2020 ◽  
Vol 8 ◽  
pp. 232470962094050
Author(s):  
Asim Kichloo ◽  
Najma Nawaz ◽  
Jagmeet Singh ◽  
Michael Aljadah ◽  
Michael Stanley Albosta ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease ◽  
Monoclonal Gammopathy ◽  
Organ Damage ◽  
Direct Effects ◽  
Monoclonal Protein ◽  
Renal Manifestation ◽  
Plasma Cell Disorder ◽  
Cell Disorder ◽  
Undetermined Significance

Monoclonal gammopathy of undetermined significance is a precursor to multiple myeloma characterized by monoclonal gammopathy without evidence of end organ damage. Some patients with clonal plasma cell disorder that do not meet the requirements for multiple myeloma have been seen to develop pathologic renal disease due to direct effects from deposition of monoclonal protein, referred to as monoclonal gammopathy of renal significance. In this article, we present a rare renal manifestation of monoclonal gammopathy of renal significance as focal segmental glomerulosclerosis.

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4830-4830
Author(s):  
Martina Kleber ◽  
Gabriele Ihorst ◽  
Christian Jakob ◽  
Peter Liebisch ◽  
Bernd Koch ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Impairment ◽  
Renal Disease ◽  
Performance Status ◽  
High Dose Chemotherapy ◽  
Disease Stage ◽  
High Dose ◽  
Novel Therapy ◽  
Normal Ranges ◽  
Ckd Stage

Abstract Renal impairment (RI) of varying severity including end stage renal disease is a common manifestation of multiple myeloma (MM). Nevertheless, the influence of milder - and via creatinine (crea) determination invisible - RI as a risk factor in MM patients (pts) is less well defined. We have previously reported in 167 cancer pts that estimating the glomerular filtration rate (eGFR) as compared to serum crea- or cystatin-levels determines prognostically adverse risk groups (Ann Oncol18: 950–8, 2007). In order to analyze the frequency of RI stages in a homogenous pt group, we determined RI in 198 consecutive MM pts receiving standard (Std; n=103) or high-dose chemotherapy (hd-CTx; n=95) in a multi-center study. We analyzed disease-stage, sex, age, performance status, β2-microglobulin, serum crea and GFR calculated by both the four-component “Modification of Diet in Renal Disease” (MDRD) and Cockcroft-Gault (CG). Evaluated outcomes were overall survival (OS) and progression free survival (PFS). Of note, although median crea, MDRD- and CG-eGFR-values appeared almost normal with 0.9mg/dl, 87 and 82ml/min/1.73m2, respectively, RI as determined as advanced chronic kidney disease (CKD stage >3 = eGFR<60) was apparent in 25% of all pts. We also observed distinct differences in pts receiving Std vs. hd-CTx: the median age was higher with 67 years (y) in the Std vs. 57y in the hd-CTx group (p<0.05). Advanced disease, as defined as number of pts with Durie & Salmon stage II/III, was comparable in both groups (92 vs. 97%, respectively). Although the crea was still within normal ranges in the Std- (1mg/dl) vs. hd-CTx-pts (0.8mg/dl), MDRD- and CG-formulas uncovered relevant differences between both groups: both MDRD- and CG-eGFRs being significantly decreased in Std- vs. hd-CTx-pts (MDRD: 72 vs. 96; CG: 68 vs. 101, respectively; p<0.05). Correspondingly, more Std-pts showed a decreased eGFR <60 than hd-CTx-pts (34 vs. 14%). Comparing solely those Std vs. hd-CTx-pts with active, progressing and/or proliferating myeloma also ascertained significant eGFR-differences in terms of decreased MDRD- and CG-levels, as well as more pts with CKD stage 3–5 in the Std group. This suggests that these MM pts had a significantly different renal function in Std-pts, most reliably, however, only detected via eGFR and CKD staging assessment, rather than the serum crea alone. Associated with RI (eGFR <60), PFS and OS were significantly decreased as compared to eGFR values >60 with estimated median values of 15 vs. 20 months and 36 vs. 61.3 months, respectively (p<0.05). In line, PFS and OS for Std- and hd-CTx-pts for eGFR<60 were considerably lower as compared to pts with eGFRs>60. In conclusion, we highlight the importance of efficiently detecting RI by means of eGFR-assessment, which allows to detect MM pts with mild - and/or via crea determination invisible - RI. Our data demonstrate that eGFR-decline substantially diminishes PFS and OS in consecutive MM pts, and suggest that with RI, Std- as opposed to hd-therapies do not substantially improve PFS/OS, so that novel therapy approaches are especially needed for those pts with RI, not receiving hd-CTx. These findings should also hold true for other cancer pts.

scholarly journals Extracorporeal Apheresis Via AV Fistula in Multiple Myeloma Patients with End Stage Renal Disease

2016 ◽  
Vol 22 (3) ◽  
pp. S443-S444
Author(s):  
Jennifer Bourke ◽  
Tomer M. Mark ◽  
Jeffrey Silberzweig ◽  
Uvannie Enriquez ◽  
Koen van Besien ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Av Fistula ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document